The role of primary care prescribers in the diagnosis and management of community-associated methicillin-resistant staphylococcus aureus skin and soft tissue infections

American Journal of Therapeutics

Volumn 16, Issue 4, 2009, Pages 333-338

  Lawrence, Kenneth R ^a,b   Golik, Monica V ^c   Davidson, Lisa ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c WATERBURY HOSPITAL   (United States)

Author keywords

CA MRSA; Community associated methicillin resistant Staphylococcus aureus; Skin and soft tissue infections

Indexed keywords

CEFALEXIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ABSCESS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTEREMIA; BACTERIUM ISOLATE; BODY FLUID DISCOLOR; CARBUNCLE; CELLULITIS; CLOSTRIDIUM DIFFICILE INFECTION; ENDOCARDITIS; FURUNCULOSIS; HEALTH CARE; HOSPITAL INFECTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYALGIA; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; OPTIC NEURITIS; PERCUTANEOUS DRAINAGE; PHOTOSENSITIVITY; PNEUMONIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RASH; REDMAN SYNDROME; REVIEW; SKIN INFECTION; SKIN STRUCTURE; SOFT TISSUE INFECTION; SPIDER BITE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CLINDAMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DOXYCYCLINE; DRUG PRESCRIPTIONS; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINOCYCLINE; OFLOXACIN; PRIMARY HEALTH CARE; PROFESSIONAL ROLE; QUINOLINES; RISK FACTORS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 68949187746     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31817fdea8     Document Type: Review

References (35)

1. Barrett FF, McGehee RF Jr, Finland M. Methicillin-resistant Staphylococcus aureus at Boston City Hospital: bacteriologic and epidemiologic observations. N Engl J Med. 1968;279:441-448.
2. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007; 13:1840-1846.
3. Klevens RM, Morrison MA, Nadle J, et al, and the Active Bacterial Core Surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763-1771.
4. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and healthcare-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003; 290:2976-2984.
5. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA. 2001 ;286: 1201-1205.
6. Johnson JK, Khoie T, Shurland S, et al. Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone. Emerg Infect Dis. 2007;13:11195-11200.
7. Millar BC, Prendergast BD, Moore JE. Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis. J Antimicrob Chemother. 2008;61: 1-7.
8. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2007;56:325-329.
9. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Pan ton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29:1128-1132.
10. Xiao XM, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 2002;46:1147-1152.
11. Tenover FC, McDougal LK, Goering RV, et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol. 2006;44:108-118.
12. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666-674.
13. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144:309-317.
14. Hota B, Ellenbogen C, Hayden MK, et al. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections at a public; do public housing and incarceration amplify transmission? Arch Intern Med. 2007;167:1026-1033.
15. Bhattacharya D, Carleton H, Tsai CJ, et al. Differences in clinical and molecular characteristics of skin and soft tissue methicillin-resistant Staphylococcus aureus isolates between two hospitals in Northern California. J Clin Microbiol. 2007;45:1798-1803.
16. Davis SL, Perri MB, Donabedian SM, et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol. 2007;45: 1705-1711.
17. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin- susceptible S aureus infection: a prospective investigation. Clin Infect Dis. 2007; 44:471-482.
18. Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community: summary of an expert's meeting convened by the CDC. Atlanta, GA: Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA-ExpMtgStrategies.pdf. Accessed January 2, 2008.
19. Miller LG, Perdreau-Remington F, Rieg G, et al. Necro-tizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352:1445-1453.
20. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med. 2005;353:1245-1251.
21. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-1406.
22. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin- resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004;23:123-127.
23. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemo-ther. 2007;51:4044-4048.
24. Ruhe JJ, Smith N, Bradsher RW, et al. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007;44:777-784.
25. Gupta K, MacIntyre A, Vanasse G, et al. Trends in prescribing b-lactam antibiotics for treatment of community-associated methicillin-resistant Staphylococcus aureus infections. J Clin Microbiol. 2007;5:3930-3934.
26. Daun RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007;357:380-390.
27. Szumowski JD, Cohen DE, Kanaya F, et al. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother. 2007;51:423-428.
28. Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007; 51:3298-3303.
29. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46:584-593.
30. Skiest DJ, Brown K, Cooper TW, et al. Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients. J Infect. 2007;54: 427-434.
31. Cenizal MJ, Skiest D, Luber S, et al. Prospective trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin- resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007; 51:2628-2630.
32. Lewis JS III, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis. 2005;40:280-285.
33. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med. 2005;45:311-320.
34. Centers for Disease Control and Prevention. Community-Acquired MRSA Information for the Public. Available at: http://www.cdc.gov/ncidod/dhqp/ar- mrsa-ca-public.html. Accessed February 14, 2008.
35. O'Connor RE. Effective Antibiotic Treatment of MRSA. ClinicalTrials.gov identifier: NCT00388310.